

Luis Miguel Ruilope

List of Publications by Citations

Source: <https://exaly.com/author-pdf/611942/luis-miguel-ruilope-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 165 papers | 27,252 citations | 41 h-index | 165 g-index |
| 192 ext. papers | 34,542 ext. citations | 7.7 avg, IF | 6.46 L-index |

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 165 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2016 , 37, 2129-2200 | 9.5 | 7751 |
| 164 | 2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104 | 9.5 | 3698 |
| 163 | 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219 | 9.5 | 3400 |
| 162 | 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2007 , 28, 1462-536 | 9.5 | 1418 |
| 161 | 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 1953-1985 | 1.9 | 1262 |
| 160 | European Society of Hypertension position paper on ambulatory blood pressure monitoring. <i>Journal of Hypertension</i> , 2013 , 31, 1731-68 | 1.9 | 898 |
| 159 | 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. <i>Journal of Hypertension</i> , 2007 , 25, 1751-62 | 1.9 | 871 |
| 158 | Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. <i>New England Journal of Medicine</i> , 2011 , 364, 907-17 | 59.2 | 591 |
| 157 | European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. <i>Journal of Hypertension</i> , 2008 , 26, 1505-26 | 1.9 | 578 |
| 156 | Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. <i>Hypertension</i> , 2011 , 57, 898-902 | 8.5 | 547 |
| 155 | 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. <i>Blood Pressure</i> , 2014 , 23, 3-16 | 1.7 | 474 |
| 154 | Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. <i>Lancet, The</i> , 2010 , 375, 1255-66 | 40 | 372 |
| 153 | Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020 , 383, 2219-2229 | 59.2 | 347 |
| 152 | Avosentan for overt diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 527-35 | 12.7 | 346 |
| 151 | Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 884-94 | 27.4 | 342 |
| 150 | Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. <i>Journal of the American Society of Nephrology: JASN</i> , 2001 , 12, 218-225 | 12.7 | 329 |
| 149 | Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. <i>New England Journal of Medicine</i> , 2018 , 378, 1509-1520 | 59.2 | 327 |

| | | | |
|-----|--|------|-----|
| 148 | Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. <i>Hypertension</i> , 2009 , 53, 466-72 | 8.5 | 270 |
| 147 | A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. <i>Journal of Hypertension</i> , 2011 , 29, 980-90 | 1.9 | 151 |
| 146 | High prevalence of masked uncontrolled hypertension in people with treated hypertension. <i>European Heart Journal</i> , 2014 , 35, 3304-12 | 9.5 | 132 |
| 145 | Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012 , 33, 2782-95 | 9.5 | 121 |
| 144 | Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 2252-2263 | 59.2 | 103 |
| 143 | Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , 2019 , 40, 3474-3482 | 9.5 | 95 |
| 142 | Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019 , 50, 345-356 | 4.6 | 80 |
| 141 | Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH). <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 620-640 | 4.3 | 79 |
| 140 | Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?. <i>American Journal of Hypertension</i> , 2014 , 27, 680-7 | 2.3 | 78 |
| 139 | Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021 , 143, 540-552 | 16.7 | 76 |
| 138 | Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study. <i>Journal of Hypertension</i> , 2012 , 30, 713-9 | 1.9 | 74 |
| 137 | Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 285-94 | 7.4 | 72 |
| 136 | Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019 , 50, 333-344 | 4.6 | 70 |
| 135 | Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study. <i>Hypertension</i> , 2015 , 66, 750-6 | 8.5 | 69 |
| 134 | Renal function and target organ damage in hypertension. <i>European Heart Journal</i> , 2011 , 32, 1599-604 | 9.5 | 67 |
| 133 | Prognostic Value of Masked Uncontrolled Hypertension. <i>Hypertension</i> , 2018 , 72, 862-869 | 8.5 | 61 |
| 132 | Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. <i>European Heart Journal</i> , 2015 , 36, 1967-73 | 9.5 | 58 |
| 131 | Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?. <i>Kidney International</i> , 2014 , 85, 536-46 | 9.9 | 48 |

| | | | |
|-----|--|------|----|
| 130 | Current challenges in the clinical management of hypertension. <i>Nature Reviews Cardiology</i> , 2011 , 9, 267-275 | 15.8 | 48 |
| 129 | Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors. <i>Hypertension</i> , 1996 , 28, 967-72 | 8.5 | 48 |
| 128 | Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. <i>Journal of Hypertension</i> , 2009 , 27, 673-9 | 1.9 | 45 |
| 127 | Renal Denervation in High-Risk Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2879-2888 | 15.1 | 41 |
| 126 | Urinary albumin excretion is associated with nocturnal systolic blood pressure in resistant hypertensives. <i>Hypertension</i> , 2011 , 57, 556-60 | 8.5 | 41 |
| 125 | Chronic kidney disease in Spain: Prevalence and impact of accumulation of cardiovascular risk factors. <i>Nefrologia</i> , 2018 , 38, 606-615 | 1.5 | 40 |
| 124 | Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Hypertension</i> , 2019 , 37, 2307-2324 | 1.9 | 36 |
| 123 | Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. <i>Journal of Hypertension</i> , 2014 , 32, 2082-91; discussion 2091 | 1.9 | 35 |
| 122 | Prevalence and Clinical Characteristics of Refractory Hypertension. <i>Journal of the American Heart Association</i> , 2017 , 6, | 6 | 34 |
| 121 | Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. <i>Journal of Hypertension</i> , 2012 , 30, 204-9 | 1.9 | 34 |
| 120 | Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. <i>Kidney International</i> , 2004 , S45-9 | 9.9 | 34 |
| 119 | Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.. <i>European Heart Journal</i> , 2021 , | 9.5 | 33 |
| 118 | Lifestyle interventions for the prevention and treatment of hypertension. <i>Nature Reviews Cardiology</i> , 2021 , 18, 251-275 | 14.8 | 33 |
| 117 | KLK1 and ZG16B proteins and arginine-proline metabolism identified as novel targets to monitor atherosclerosis, acute coronary syndrome and recovery. <i>Metabolomics</i> , 2015 , 11, 1056-1067 | 4.7 | 31 |
| 116 | Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. <i>Clinical Science</i> , 2016 , 130, 525-38 | 6.5 | 28 |
| 115 | Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. <i>Journal of Hypertension</i> , 2017 , 35, 2388-2394 | 1.9 | 28 |
| 114 | The kidney as a sensor of cardiovascular risk in essential hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13 Suppl 3, S165-8 | 12.7 | 28 |
| 113 | Impact of Ambulatory Blood Pressure Monitoring on Reclassification of Hypertension Prevalence and Control in Older People in Spain. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 453-61 | 2.3 | 27 |

| | | | |
|-----|--|------|----|
| 112 | Short-Term and Long-Term Reproducibility of Hypertension Phenotypes Obtained by Office and Ambulatory Blood Pressure Measurements. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 927-33 | 2.3 | 26 |
| 111 | Prevalence of Masked Hypertension in Untreated and Treated Patients With Office Blood Pressure Below 130/80 mm Hg. <i>Circulation</i> , 2018 , 137, 2651-2653 | 16.7 | 25 |
| 110 | Citric Acid Metabolism in Resistant Hypertension: Underlying Mechanisms and Metabolic Prediction of Treatment Response. <i>Hypertension</i> , 2017 , 70, 1049-1056 | 8.5 | 25 |
| 109 | Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1131 | 5.6 | 25 |
| 108 | Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. <i>Nature Reviews Endocrinology</i> , 2017 , 13, 365-374 | 15.2 | 24 |
| 107 | Global cardiovascular protection in chronic kidney disease. <i>Nature Reviews Cardiology</i> , 2016 , 13, 603-8 | 14.8 | 24 |
| 106 | Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience. <i>European Journal of Clinical Investigation</i> , 2016 , 46, 92-8 | 4.6 | 24 |
| 105 | Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 1864-1875 | 4.3 | 24 |
| 104 | Variations in 24-Hour BP Profiles in Cohorts of Patients with Kidney Disease around the World: The I-DARE Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 1348-1357 | 6.9 | 23 |
| 103 | Comparison of agents that affect aldosterone action. <i>Seminars in Nephrology</i> , 2014 , 34, 285-306 | 4.8 | 23 |
| 102 | Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017 , 8, 44217-44231 | 3.3 | 23 |
| 101 | Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019 , 40, 880-886 | 9.5 | 23 |
| 100 | Magnitude of Hypotension Based on Office and Ambulatory Blood Pressure Monitoring: Results From a Cohort of 5066 Treated Hypertensive Patients Aged 80 Years and Older. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 452.e1-452.e6 | 5.9 | 21 |
| 99 | Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. <i>Cardiovascular Diabetology</i> , 2016 , 15, 8 | 8.7 | 21 |
| 98 | Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 915-25 | 5.9 | 21 |
| 97 | Clinic Versus Daytime Ambulatory Blood Pressure Difference in Hypertensive Patients: The Impact of Age and Clinic Blood Pressure. <i>Hypertension</i> , 2017 , 69, 211-219 | 8.5 | 20 |
| 96 | Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2020 , | 4.3 | 20 |
| 95 | Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensives. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 714-23 | | 20 |

| | | | |
|----|---|------|----|
| 94 | An update of the blockade of the renin angiotensin aldosterone system in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2283-92 | 4 | 19 |
| 93 | Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progression. <i>Translational Research</i> , 2016 , 178, 25-37.e7 | 11 | 19 |
| 92 | Ambulatory blood pressure in hypertensive patients with inclusion criteria for the SPRINT trial. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 947-953.e5 | | 19 |
| 91 | Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. <i>Diabetes Care</i> , 2016 , 39, 1729-37 | 14.6 | 17 |
| 90 | A guide for easy- and difficult-to-treat hypertension. <i>International Journal of Cardiology</i> , 2014 , 172, 17-23.2 | | 17 |
| 89 | Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017 , 8, 15553-15562 | 3.3 | 17 |
| 88 | Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 142-152 | 15.1 | 17 |
| 87 | Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics. <i>International Journal of Cardiology</i> , 2015 , 196, 170-7 | 3.2 | 16 |
| 86 | Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY Registry. <i>Journal of Hypertension</i> , 2017 , 35, 148-153 | 1.9 | 15 |
| 85 | Frailty, Disability, and Ambulatory Blood Pressure in Older Adults. <i>Journal of the American Medical Directors Association</i> , 2018 , 19, 433-438 | 5.9 | 15 |
| 84 | Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016 , 2, 119-30 | 6.4 | 15 |
| 83 | Trends in hypertension control among the older population of Spain from 2000 to 2001 to 2008 to 2010: role of frequency and intensity of drug treatment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 67-76 | 5.8 | 15 |
| 82 | Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators. <i>Hypertension</i> , 2016 , 68, 157-66 | 8.5 | 14 |
| 81 | Does cardiovascular protection translate into renal protection?. <i>Nature Reviews Cardiology</i> , 2014 , 11, 742-6 | 14.8 | 14 |
| 80 | Exercise Reduces Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2020 , 9, e018487 | 6 | 14 |
| 79 | Enhanced Klotho availability protects against cardiac dysfunction induced by uraemic cardiomyopathy by regulating Ca handling. <i>British Journal of Pharmacology</i> , 2020 , 177, 4701-4719 | 8.6 | 14 |
| 78 | Hypertension and obesity: correlates with renin-angiotensin-aldosterone system and uric acid. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 559-60 | 2.3 | 13 |
| 77 | Validation of a therapeutic scheme for the treatment of resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2011 , 5, 498-504 | | 13 |

| | | | |
|----|--|------|----|
| 76 | The year in cardiovascular medicine 2020: epidemiology and prevention. <i>European Heart Journal</i> , 2021 , 42, 813-821 | 9.5 | 13 |
| 75 | An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk. <i>Frontiers in Physiology</i> , 2021 , 12, 632260 | 4.6 | 12 |
| 74 | Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention. <i>Atherosclerosis</i> , 2019 , 282, 67-74 | 3.1 | 12 |
| 73 | Has the SPRINT trial introduced a new blood-pressure goal in hypertension?. <i>Nature Reviews Cardiology</i> , 2017 , 14, 560-566 | 14.8 | 11 |
| 72 | Renin-angiotensin system blockade: Finerenone. <i>Nephrologie Et Therapeutique</i> , 2017 , 13 Suppl 1, S47-S53. | 3.6 | 11 |
| 71 | Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Fröhner Rats, a Genetic Model of Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2020 , 51, 294-303 | 4.6 | 11 |
| 70 | Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria. <i>Scientific Reports</i> , 2017 , 7, 8894 | 4.9 | 11 |
| 69 | Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021 , | 4.3 | 10 |
| 68 | Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. <i>Hypertension</i> , 2019 , 74, 130-136 | 8.5 | 9 |
| 67 | Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9-Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA. <i>Frontiers in Immunology</i> , 2017 , 8, 853 | 8.4 | 9 |
| 66 | Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. <i>European Heart Journal</i> , 2020 , 41, 2067-2069 | 9.5 | 8 |
| 65 | Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals. <i>Scientific Reports</i> , 2018 , 8, 4802 | 4.9 | 8 |
| 64 | Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 126-31 | 6.4 | 8 |
| 63 | Pharmacological reasons that may explain why randomized clinical trials have failed in acute heart failure syndromes. <i>International Journal of Cardiology</i> , 2017 , 233, 1-11 | 3.2 | 7 |
| 62 | How can resistant hypertension be identified and prevented?. <i>Nature Reviews Cardiology</i> , 2013 , 10, 293-304. | 6.8 | 7 |
| 61 | Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014 , 41, 30-6 | 3 | 7 |
| 60 | Oxidative Status before and after Renal Replacement Therapy: Differences between Conventional High Flux Hemodialysis and on-Line Hemodiafiltration. <i>Nutrients</i> , 2019 , 11, | 6.7 | 7 |
| 59 | White-coat UnControlled Hypertension, Masked UnControlled Hypertension, and True UnControlled Hypertension, phonetic and mnemonic terms for treated hypertension phenotypes. <i>Journal of Hypertension</i> , 2018 , 36, 446-447 | 1.9 | 6 |

| | | | |
|----|--|------|---|
| 58 | Chronic kidney disease: Blood pressure control in CKD--still a matter of debate. <i>Nature Reviews Nephrology</i> , 2013 , 9, 572-3 | 14.9 | 6 |
| 57 | Association of clinic and ambulatory heart rate parameters with mortality in hypertension. <i>Journal of Hypertension</i> , 2020 , 38, 2416-2426 | 1.9 | 6 |
| 56 | A review of chemical therapies for treating diabetic hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 909-923 | 4 | 5 |
| 55 | Lifetime cardiovascular risk is associated with a multimarker score of systemic oxidative status in young adults independently of traditional risk factors. <i>Translational Research</i> , 2019 , 212, 54-66 | 11 | 5 |
| 54 | Ambulatory and home blood pressure monitoring in people with chronic kidney disease. Time to abandon clinic blood pressure measurements?. <i>Current Opinion in Nephrology and Hypertension</i> , 2015 , 24, 488-91 | 3.5 | 5 |
| 53 | Microalbuminuria and cardiorenal risk: old and new evidence in different populations. <i>F1000Research</i> , 2019 , 8, | 3.6 | 5 |
| 52 | Physical exercise and epicardial adipose tissue: A systematic review and meta-analysis of randomized controlled trials. <i>Obesity Reviews</i> , 2021 , 22, e13103 | 10.6 | 5 |
| 51 | Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. <i>Nefrologia</i> , 2019 , 39, 184-191 | 0.4 | 4 |
| 50 | Retraction: Banegas JR et al. Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. <i>N Engl J Med</i> 2018;378:1509-20. <i>New England Journal of Medicine</i> , 2020 , 382, 786 | 59.2 | 4 |
| 49 | Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective. <i>Journal of Hypertension</i> , 2020 , 38, 1005-1015 | 1.9 | 4 |
| 48 | Urinary metabolic signatures reflect cardiovascular risk in the young, middle-aged, and elderly populations. <i>Journal of Molecular Medicine</i> , 2020 , 98, 1603-1613 | 5.5 | 4 |
| 47 | Resistant hypertension: new insights and therapeutic perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 188-193 | 6.4 | 4 |
| 46 | Ambulatory Blood Pressure and Mortality. <i>New England Journal of Medicine</i> , 2018 , 379, 1287-8 | 59.2 | 4 |
| 45 | Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease. <i>Hypertension Research</i> , 2020 , 43, 696-704 | 4.7 | 3 |
| 44 | Translational science in albuminuria: a new view of albuminuria under chronic RAS suppression. <i>Clinical Science</i> , 2018 , 132, 739-758 | 6.5 | 3 |
| 43 | The impact of antihypertensives on kidney disease. <i>F1000Research</i> , 2017 , 6, 611 | 3.6 | 3 |
| 42 | Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 , | 12.7 | 3 |
| 41 | TCA Cycle and Fatty Acids Oxidation Reflect Early Cardiorenal Damage in Normoalbuminuric Subjects with Controlled Hypertension. <i>Antioxidants</i> , 2021 , 10, | 7.1 | 3 |

| | | | |
|----|---|------|---|
| 40 | Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. <i>Nefrologia</i> , 2019 , 39, 184-191 | 1.5 | 3 |
| 39 | LCZ696, The Need for an Indication in Arterial Hypertension. <i>American Journal of Hypertension</i> , 2015 , 28, 1403-4 | 2.3 | 2 |
| 38 | Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. <i>Nefrologia</i> , 2020 , 40, 439-445 | 0.4 | 2 |
| 37 | Novel molecular plasma signatures on cardiovascular disease can stratify patients throughout life. <i>Journal of Proteomics</i> , 2020 , 222, 103816 | 3.9 | 2 |
| 36 | Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. <i>Nefrologia</i> , 2020 , 40, 440-445 | 1.5 | 2 |
| 35 | The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23.. <i>BMC Medicine</i> , 2022 , 20, 14 | 11.4 | 2 |
| 34 | Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension. <i>Hypertension</i> , 2019 , 73, 794-802 | 8.5 | 2 |
| 33 | Oxidized Low-Density Lipoprotein Associates with Ventricular Stress in Young Adults and Triggers Intracellular Ca Alterations in Adult Ventricular Cardiomyocytes. <i>Antioxidants</i> , 2020 , 9, | 7.1 | 2 |
| 32 | Variations in Circulating Active MMP-9 Levels During Renal Replacement Therapy. <i>Biomolecules</i> , 2020 , 10, | 5.9 | 2 |
| 31 | Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology. <i>Antioxidants and Redox Signaling</i> , 2021 , 35, 602-617 | 8.4 | 2 |
| 30 | Association Between Improvement in Cardiovascular Risk Profile and Changes in Sickness Absence: Results of the ICARIA Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017 , 70, 941-951 | 0.7 | 1 |
| 29 | How do ultrafine particles in urban air affect ambulatory blood pressure?. <i>Journal of Hypertension</i> , 2020 , 38, 845-849 | 1.9 | 1 |
| 28 | Prognostic Relevance of Short-Term Blood Pressure Variability: The Spanish ABPM Registry. <i>Hypertension</i> , 2020 , HYPERTENSIONAHA11914508 | 8.5 | 1 |
| 27 | The use of antihypertensive fixed combinations in clinical practice needs a reappraisal. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 716-717 | 2.3 | 1 |
| 26 | Second denervation in a patient with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2016 , 105, 880-3 | 6.1 | 1 |
| 25 | Impact of the new American and British guidelines on the management and treatment of dyslipidemia in a Spanish working population. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014 , 67, 906-11 | 0.7 | 1 |
| 24 | Proteomic Analysis of Blood Extracellular Vesicles in Cardiovascular Disease by LC-MS/MS Analysis. <i>Methods in Molecular Biology</i> , 2017 , 1619, 141-149 | 1.4 | 1 |
| 23 | Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation. <i>Diseases (Basel, Switzerland)</i> , 2017 , 5, | 4.4 | 1 |

| | | | |
|----|--|-----|---|
| 22 | Blood pressure and uric acid in diabetes mellitus. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 269 | 2.3 | 1 |
| 21 | Arterial hypertension and vascular medicine. <i>Clinical Science</i> , 1996 , 90, 159-60 | 6.5 | 1 |
| 20 | Acute Aerobic Exercise Induces Short-Term Reductions in Ambulatory Blood Pressure in Patients With Hypertension: A Systematic Review and Meta-Analysis. <i>Hypertension</i> , 2021 , 78, 1844-1858 | 8.5 | 1 |
| 19 | Hypertension in Diabetic Kidney Disease 2019 , 325-335 | | 1 |
| 18 | Genetic Deletion of NOD1 Prevents Cardiac Ca Mishandling Induced by Experimental Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020 , 21, | 6.3 | 1 |
| 17 | May Measurement Month 2018: an analysis of blood pressure screening results from Spain. <i>European Heart Journal Supplements</i> , 2020 , 22, H119-H121 | 1.5 | 1 |
| 16 | SPRINT. Counteracting the risk of prehypertension?. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 546-547 | | 1 |
| 15 | New Strategy to Control Blood Pressure: Interactive Mobile Phone Support. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 109-10 | 2.3 | 1 |
| 14 | Analysis of Global Oxidative Status Using Multimarker Scores Reveals a Specific Association Between Renal Dysfunction and Diuretic Therapy in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021 , 76, 1198-1205 | 6.4 | 1 |
| 13 | Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets. <i>Frontiers in Physiology</i> , 2021 , 12, 775029 | 4.6 | 0 |
| 12 | TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome. <i>Journal of Pathology</i> , 2021 , 254, 5-19 | 9.4 | 0 |
| 11 | Early renal and vascular damage within the normoalbuminuria condition. <i>Journal of Hypertension</i> , 2021 , 39, 2220-2231 | 1.9 | 0 |
| 10 | Hypertension in Latin/Hispanic Population 2018 , 15-20 | | 0 |
| 9 | Sacubitril/valsartan in the treatment of arterial hypertension: an unaccomplished promise?. <i>Hypertension Research</i> , 2017 , 40, 439-440 | 4.7 | |
| 8 | Are the guidelines of the ISH devoted to a population not contemplated in the ACC/AHA guidelines?. <i>International Journal of Cardiology: Hypertension</i> , 2020 , 7, 100068 | 1.6 | |
| 7 | On the need of the simultaneous control of arterial hypertension and diabetes mellitus. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 221-222 | 2.3 | |
| 6 | Comment on the Management of resistant hypertension in a multidisciplinary unit of renal denervation: protocol and results. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013 , 66, 830-9 | 9.7 | |
| 5 | Management of resistant hypertension in a multidisciplinary unit of renal denervation: protocol and results. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013 , 66, 364-70 | 0.7 | |

- | | | |
|---|---|------|
| 4 | Systemic lupus erythematosus and cardiovascular disease. <i>International Journal of Cardiology: Hypertension</i> , 2020 , 7, 100065 | 1.6 |
| 3 | Age and blood pressure goal in women with prior coronary events. <i>International Journal of Cardiology: Hypertension</i> , 2020 , 7, 100059 | 1.6 |
| 2 | Response to Letter to the Editor. <i>Obesity Reviews</i> , 2021 , 22, e13253 | 10.6 |
| 1 | New vascular biomarkers related to ABPM phenotypes in untreated patients. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 53-54 | 2.3 |